target menu
 

Prof. Ronald de Wit, MD Phd (group leader Experimental Systematic Therapy of Urogenital Cancers)

Research coordinator/ group leader

Ronald de WitMy research focus is Urological Oncology. I have been appointed chairman of the EORTC-Genitourinary Group Chemotherapy Committee for 9 years (max 3 terms) and initiated and led randomized studies in testicular cancer (EORTC 30941, 30948, 30982 and 30983) and bladder cancer (30986, 30987 and 30994). I co-chaired the International trial TAX 327, investigating docetaxel vs mitoxantrone in mCRPC and I am PI or SCM in several recent or ongoing clinical phase 2 and 3 studies in urological cancers. I am member of several National and European Consensus Committees on the management of urological cancers and I am member of a wide range of professional societies and committees and served as Faculty Member of the American Society of Clinical Oncology and the European Society of Medical Oncology (1999-2015). Having a keen interest in both early and late drug development I serve in Industry Scientific Advisory Board Committees and was closely involved in the approval of several medicinal products by FDA and EMA. I chair Independent DMCs of registration trials of new medicinal products from several Pharmaceutical Companies. I collaborate with the departments of Urology and Pathology of The Cancer Institute in preclinical research in prostate cancer cell line and xenograft models. I was board member of the Dutch Cancer Foundation (Queen Wilhelmina Foundation) and  board member of the Netherlands Society of Medical Oncology and its advisory panel on new drugs in oncology. In 2011 I launched the Dutch Uro- Oncology Studygroup (DUOS), creating a network of 34 academic and supraregional hospitals in the Netherlands, with a research interest in Clinical Uro-Oncology. I am the current Chair of DUOS and we are accruing in numerous phase 2 and 3, Investigator initiated as well as Industry sponsored clinical trials. My list of publications include over 300 papers and book chapters.